Literature DB >> 19366850

FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study.

Belinda J Schouten1, Penelope J Hunt, John H Livesey, Chris M Frampton, Steven G Soule.   

Abstract

CONTEXT: Parenteral iron administration has been associated with hypophosphatemia. Fibroblast growth factor 23 (FGF23) has a physiological role in phosphate homeostasis via suppression of 25-hydroxyvitamin D [25(OH)D] activation and promotion of phosphaturia. We recently reported a case of iron-induced hypophosphatemic osteomalacia associated with marked FGF23 elevation.
OBJECTIVE: Our objective was to prospectively investigate the effect of parenteral iron polymaltose on phosphate homeostasis and to determine whether any observed change was related to alterations in circulating FGF23. DESIGN, SETTING, AND PARTICIPANTS: Eight medical outpatients prescribed iv iron polymaltose were recruited. Plasma phosphate, 25(OH)D, 1,25-dihydroxyvitamin D [1,25(OH)(2)D], PTH, FGF23, and urinary tubular reabsorption of phosphate were measured prior to iron administration and then weekly for a minimum of 3 wk.
RESULTS: Plasma phosphate fell from 3.4 +/- 0.6 mg/dl at baseline to 1.8 +/- 0.6 mg/dl at wk 1 (P < 0.0001) associated with a fall in percentage tubular reabsorption of phosphate (90 +/- 4.8 to 68 +/- 13; P < 0.001) and 1,25(OH)(2)D (54 +/- 25 to 9 +/- 8 pg/ml; P < 0.001). These indices remained significantly suppressed at wk 2 and 3. 25(OH)D levels were unchanged. FGF23 increased significantly from 43.5 pg/ml at baseline to 177 pg/ml at wk 1 (P < 0.001) with levels correlating with both serum phosphate (R = -0.74; P <0.05) and 1,25(OH)(2)D (R = -0.71; P < 0.05).
CONCLUSION: Parenteral iron suppresses renal tubular phosphate reabsorption and 1alpha-hydroxylation of vitamin D resulting in hypophosphatemia. Our data suggest that this is mediated by an increase in FGF23.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366850     DOI: 10.1210/jc.2008-2396

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  79 in total

1.  Randomized trial of intravenous iron-induced hypophosphatemia.

Authors:  Myles Wolf; Glenn M Chertow; Iain C Macdougall; Robert Kaper; Julie Krop; William Strauss
Journal:  JCI Insight       Date:  2018-12-06

Review 2.  Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Authors:  David B Bregman; Lawrence T Goodnough
Journal:  Ther Adv Hematol       Date:  2014-04

Review 3.  Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Authors:  David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith
Journal:  Am J Kidney Dis       Date:  2015-02-26       Impact factor: 8.860

Review 4.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

5.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Authors:  Emily G Farrow; Xijie Yu; Lelia J Summers; Siobhan I Davis; James C Fleet; Matthew R Allen; Alexander G Robling; Keith R Stayrook; Victoria Jideonwo; Martin J Magers; Holly J Garringer; Ruben Vidal; Rebecca J Chan; Charles B Goodwin; Siu L Hui; Munro Peacock; Kenneth E White
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

6.  What's new in FGF23 research?

Authors:  Seiji Fukumoto
Journal:  Bonekey Rep       Date:  2012-07-04

7.  Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.

Authors:  Akira Iguchi; Suguru Yamamoto; Mihoko Yamazaki; Kazuyuki Tasaki; Yasushi Suzuki; Junichiro James Kazama; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2017-11-27       Impact factor: 2.801

8.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

Review 9.  Fibroblast growth factor 23 and acute kidney injury.

Authors:  Javier A Neyra; Orson W Moe; Ming Chang Hu
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

10.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.

Authors:  Regina Goetz; Yuji Nakada; Ming Chang Hu; Hiroshi Kurosu; Lei Wang; Teruyo Nakatani; Mingjun Shi; Anna V Eliseenkova; Mohammed S Razzaque; Orson W Moe; Makoto Kuro-o; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.